•  
  •  
 

Central Asian Journal of Medicine

Abstract

Objective: Prevention, early detection and timely correction of functional liver disorders in patients with purulent-septic infection. Materials and Methods: We studied 38 patients with severe purulent-septic infection associated with diabetic foot syndrome (20), acute peritonitis (18) of appendicular origin (8), acute destructive pancreatitis (7) and blunt abdominal trauma with a rupture of the small intestine (3). All the patients described had generalization of the infectious onset with development of sepsis (30 patients) and sepsis syndrome (8 patients). All the patients had generalization of infectious origin with the development of sepsis (30) and sepsis syndrome (8). Results: In the process of intensive therapy, the hemostatic parameters studied are already improved from the 3rd day, the most pronounced in patients of the 2nd group, who received the hepatoprotector jetepar. Conclusions: The obtained data confirm the hepatoprotective and detoxifying role of jetepar drug in severe purulent-septic infection. The drug can be used in the complex therapy of such critical conditions for the prevention and assistive therapy of developing hepatic complications.

First Page

64

Last Page

71

References

1. Baykova I.E., Nikitin I.G. Medicinal lesions of the liver // Gastroenterology. - 2013. - No. 2. - p. 7-15. 2. Dibirov M.D., Briskin B.S. and others. Hepatorenal syndrome and the problem of correction of protein-energy metabolism in emergency surgery of the abdominal organs // Expert. and wedge. gastroenterol. - 2009. Volume 2. - p. 83-87. 3. Eremina E.Yu. drug damage to the liver // Gastroenterology. - 2012. Volume 1. - p 16-23. 4. Ermolova T.V. Study of the effectiveness of L-ornithine-L-aspartate (Hepa-Merz) in the prevention of postoperative complications in patients with chronic liver diseases // Gastroenterology. - 2009. Volume 5. p 26-32. 5. Ermolova Yu.V. Heptral for liver damage in critically ill patients // Ukrainian honey. journal - 2011. Volume 4. p 84-85. 6. Israilova V.K., Aitkonoin G.K. Modern ideas about liver failure and treatment methods // Tomsk State University Journal. KazNMU. - 2012. - No. 4. - S. 27-28. 7. Kucheryavy Yu.A. Hepatoprotectors: rational aspects of application: Textbook. allowance for doctors. - M., 2002. - 36 p. 8. Plotnikova E.Yu., Role of L-ornithine-L-spartate in the complex treatment of patients with hyperammonemia // Clin. Prospects for gastroenterol. and hepatol. - 2013. Volume 2. p 41-49. 9. Praunyan L.M. Comparative effectiveness of hepatoprotectors and exercise with dysfunctions and liver diseases // Tomsk State University Journal. morphol. - 2015. Volume 2. p. 286-288. 10. Sorokina E.Yu. Acute liver dysfunction in patients of the intensive care unit and metabolic therapy methods // Honey. emergency conditions. - 2015. - No. 8. - p. 35-45. 11. Khazanov A.I., Rumyantsev O.N. and other Features of medicinal and viral medicinal lesions of the liver // Kremlin medicine. - 2000. - No. 1. - S. 44-47.12. Acute or chronic liver failure: consensus recommendations of the Asian Pacific Associations for the Study of the Liver // Hepatol. Int. – 2014. – Vol. 8. – P. 453-471. 13. Andrade R.J., Agundeg J.A. et al. Pharmase genomics on drug induced liver in juri // Curr. Drug Metabol. – 2009. – Vol. 10, Issue 9. – p. 956-970. 14. ESPEN Guidelines on parenteral Nutrition // Hepatol. Clin. Nutr. – 2009. – Vol. 28. – p. 436-444. 15. Kim T.Y., Kim D.Z. Acute – on chronic liver failure // Clin. Mol. Hepatol. – 2013. – Vol. 19 (34). – p. 349-359 16. Mullen K.D., Prakash R.K. Management of covert hepatic encephalopathy // Clin. Ziver Dis. – 2012. – Vol. 16, №1. – P. 91-93. 17. Wright Y et al. Management of hepatic encephalopathy // Hepatology. – 2011. – Vol. 12. – P. 84-89. 18. Zevis J.H. Drug inclucad liver disease // Med. Clin. North Amer. – 2000. – Vol. 84. – P. 1275-1311. 19. Zucena M. J., Kaplovitz N. et al. Recurrent Drug – Induced Liver Injury // J. Hepatol. – 2013. – Vol. 4. – P. 820-827.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.